ArticleAnnals of medicine and surgery (2012)2026
Eosinophilic gastroenteritis in a 45-year-old female with epigastric abdominal pain: a rare case report.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Eosinophilic gastroenteritis (EGE) is a rare condition characterized by eosinophilic infiltration of the gastrointestinal tract, commonly presenting with abdominal pain, diarrhea, and peripheral eosinophilia. Corticosteroids are traditionally considered the mainstay of treatment. Case presentation: A 45-year-old female presented with epigastric abdominal pain. Laboratory tests revealed marked peripheral eosinophilia, and upper endoscopy with biopsies confirmed mucosal-type EGE. The patient declined corticosteroid therapy and was commenced on montelukast 10 mg daily. She achieved complete symptom resolution within 2 weeks and maintained remission over a 12-month follow-up. Clinical discussion: Corticosteroids remain the standard treatment for EGE, effectively reducing eosinophil counts and inflammatory mediators. In patients unable or unwilling to receive steroids, leukotriene receptor antagonists, such as montelukast, offer a viable alternative, demonstrating rapid symptom relief and potential for sustained remission. Conclusion: Physicians should recognize EGE and its therapeutic complexities. Montelukast may serve as an effective corticosteroid-sparing strategy, enabling early symptom resolution and long-term remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.